[{"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-001", "question": "A 52-year-old man with primary sclerosing cholangitis and ulcerative colitis maintained on vedolizumab presents with progressive jaundice, pruritus, and weight loss over 3 months. MRCP shows a dominant stricture at the hepatic hilum with intrahepatic ductal dilation. CA 19-9 is 180 U/mL. Brush cytology from ERCP is suspicious but not diagnostic for malignancy. PET-CT shows FDG avidity at the stricture with standardized uptake value (SUV) max of 6.2. Which of the following is the most appropriate next step in management?", "options": ["Proceed directly to liver transplantation without biopsy confirmation given high suspicion for cholangiocarcinoma in PSC", "Perform endoscopic ultrasound with fine-needle aspiration of the hilar mass", "Initiate neoadjuvant chemoradiation followed by liver transplantation per Mayo Clinic protocol", "Repeat ERCP with cholangioscopy and targeted biopsies of the suspicious area", "Treat as benign dominant stricture with serial stenting and repeat CA 19-9 in 3 months"], "answer": "C", "answer_index": 2, "explanation": "In patients with PSC and suspected hilar cholangiocarcinoma, the Mayo Clinic protocol for neoadjuvant chemoradiation followed by liver transplantation requires strict diagnostic criteria including biopsy confirmation or strongly suggestive findings (CA 19-9 >100 U/mL, malignant-appearing stricture on imaging). PET SUV >5.0 with suspicious cytology meets criteria for protocol enrollment. Direct transplantation without protocol adherence risks transplanting unrecognized metastatic disease. Cholangioscopy and EUS-FNA have higher risks of peritoneal seeding in potentially resectable/transplantable cases.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: PSC with UC, hilar stricture, CA19-9 >100, suspicious cytology, PET SUV >5. These findings meet criteria for a diagnostic workup for cholangiocarcinoma, but the vignette explicitly states brush cytology is 'suspicious but not diagnostic.' The next step in standard algorithms (e.g., AASLD) is to obtain a tissue diagnosis via a method like endoscopic ultrasound with fine-needle aspiration (EUS-FNA) or cholangioscopy before considering transplant protocols, which require a confirmed diagnosis. Option C (neoadjuvant therapy/transplant) is a definitive management step that is premature without a confirmed diagnosis. Main logical issue: A unique best answer exists (B or D for tissue acquisition), but the provided key (C) is not that answer. Main medical accuracy issue: Recommending a major transplant protocol without biopsy confirmation contradicts standard staging and eligibility guidelines. Minimal fix: Change the key to B or D, or revise the stem to state 'biopsy-confirmed cholangiocarcinoma' to justify C.\",\n  \"medical_accuracy_score\":  \"2\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: PSC with UC, hilar stricture, CA19-9 >100, suspicious cytology, PET SUV >5. These findings meet criteria for a diagnostic workup for cholangiocarcinoma, but the vignette explicitly states brush cytology is 'suspicious but not diagnostic.' The next step in standard algorithms (e.g., AASLD) is to obtain a tissue diagnosis via a method like endoscopic ultrasound with fine-needle aspiration (EUS-FNA) or cholangioscopy before considering transplant protocols, which require a confirmed diagnosis. Option C (neoadjuvant therapy/transplant) is a definitive management step that is premature without a confirmed diagnosis. Main logical issue: A unique best answer exists (B or D for tissue acquisition), but the provided key (C) is not that answer. Main medical accuracy issue: Recommending a major transplant protocol without biopsy confirmation contradicts standard staging and eligibility guidelines. Minimal fix: Change the key to B or D, or revise the stem to state 'biopsy-confirmed cholangiocarcinoma' to justify C.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-002", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab for 5 years presents with fatigue and dark urine. Laboratory studies show hemoglobin 7.2 g/dL (baseline 10.5), LDH 850 U/L (baseline 300), haptoglobin <10 mg/dL, and negative direct antiglobulin test. She received her last eculizumab dose 12 days ago. Peripheral blood flow cytometry shows 95% PNH clone size (granulocytes). Complement C5 level is undetectable. Which of the following is the most likely explanation for her breakthrough hemolysis?", "options": ["Development of anti-eculizumab antibodies causing drug neutralization", "C5 gene polymorphism (c.2654G→A) resulting in eculizumab-resistant C5", "Concurrent mycoplasma pneumoniae infection with cold agglutinin production", "Functional deficiency of complement factor H due to acquired mutation", "Proximal complement pathway activation via C3 convertase amplification"], "answer": "B", "answer_index": 1, "explanation": "The c.2654G→A polymorphism in the C5 gene results in a single amino acid change (p.Arg885His) that prevents eculizumab binding while maintaining C5 function, leading to breakthrough hemolysis despite adequate drug levels. This autosomal dominant mutation affects approximately 3-4% of Japanese patients and requires switching to ravulizumab or other anti-C5 agents. Anti-drug antibodies are rare with eculizumab. Mycoplasma would cause cold agglutinin disease with positive DAT. Factor H deficiency causes atypical HUS, not PNH exacerbation.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: PNH on eculizumab, breakthrough hemolysis (low Hb, high LDH, low haptoglobin), negative DAT, undetectable C5 level, last dose 12 days ago. The undetectable C5 level indicates adequate drug coverage, making C5 polymorphism (B) unlikely as it typically allows normal C5 levels. The most likely explanation is proximal complement activation (E), a known mechanism of breakthrough hemolysis due to C3 opsonization, especially with high clone size. Main logical issue: Key mismatch; unique best answer exists but is not B. Main medical accuracy issue: Key implies C5 polymorphism despite undetectable C5, which contradicts the mechanism. Minimal fix: Change key to E and adjust rationale to explain C3-mediated hemolysis with undetectable C5.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\": \n    \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: PNH on eculizumab, breakthrough hemolysis (low Hb, high LDH, low haptoglobin), negative DAT, undetectable C5 level, last dose 12 days ago. The undetectable C5 level indicates adequate drug coverage, making C5 polymorphism (B) unlikely as it typically allows normal C5 levels. The most likely explanation is proximal complement activation (E), a known mechanism of breakthrough hemolysis due to C3 opsonization, especially with high clone size. Main logical issue: Key mismatch; unique best answer exists but is not B. Main medical accuracy issue: Key implies C5 polymorphism despite undetectable C5, which contradicts the mechanism. Minimal fix: Change key to E and adjust rationale to explain C3-mediated hemolysis with undetectable C5.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-003", "question": "A 67-year-old man who underwent orthotopic liver transplantation 4 months ago for HCV cirrhosis presents with fever, cough, and hypoxemia. He is on tacrolimus and prednisone 5 mg daily. Chest CT shows multiple nodular opacities with surrounding ground-glass halos. Bronchoalveolar lavage PCR is positive for Torque teno virus (TTV) DNA at 10^8 copies/mL. Blood TTV viral load is 10^7 copies/mL. Which of the following is the most appropriate interpretation and management?", "options": ["TTV indicates severe immunosuppression; reduce tacrolimus dose and monitor for resolution", "TTV is a direct pulmonary pathogen; initiate intravenous ribavirin therapy", "TTV reactivation suggests CMV co-infection; start ganciclovir empirically", "TTV viral load has no clinical significance in this setting; pursue alternative diagnoses", "TTV indicates possible donor-derived infection; perform lung biopsy for histopathology"], "answer": "A", "answer_index": 0, "explanation": "Torque teno virus (TTV) viral load serves as a functional biomarker of overall immunosuppression in transplant recipients, with high levels indicating excessive immunosuppression and increased risk of opportunistic infections. The radiographic findings suggest invasive fungal infection (e.g., aspergillosis) in an over-immunosuppressed host. Reducing immunosuppression while evaluating for fungal pathogens is appropriate. TTV itself is not a pulmonary pathogen. There is no established antiviral therapy for TTV, and it does not specifically indicate CMV co-infection or donor-derived infection.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: post-liver transplant patient on immunosuppression, fever/cough/hypoxemia, CT showing nodules with ground-glass halos (classic for angioinvasive fungal infection like aspergillosis), high TTV load in BAL and blood. TTV is a recognized biomarker of net immunosuppression, not a direct pathogen. The keyed answer correctly interprets high TTV as indicating over-immunosuppression, guiding reduction of tacrolimus while evaluating for fungal infection. Alternatives are medically inaccurate: TTV is not a treatable pulmonary pathogen (B), not specific for CMV co‑infection (C), does have clinical significance as an immunosuppression marker (D), and is not an indication for donor-derived infection workup via lung biopsy (E). No logical contradictions; a unique best answer is supported. Medical accuracy is high. Minimal fix: none required; item is sound.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: post-liver transplant patient on immunosuppression, fever/cough/hypoxemia, CT showing nodules with ground-glass halos (classic for angioinvasive fungal infection like aspergillosis), high TTV load in BAL and blood. TTV is a recognized biomarker of net immunosuppression, not a direct pathogen. The keyed answer correctly interprets high TTV as indicating over-immunosuppression, guiding reduction of tacrolimus while evaluating for fungal infection. Alternatives are medically inaccurate: TTV is not a treatable pulmonary pathogen (B), not specific for CMV co‑infection (C), does have clinical significance as an immunosuppression marker (D), and is not an indication for donor-derived infection workup via lung biopsy (E). No logical contradictions; a unique best answer is supported. Medical accuracy is high. Minimal fix: none required; item is sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-004", "question": "A 44-year-old woman with autoimmune hepatitis-primary biliary cholangitis overlap syndrome on ursodeoxycholic acid and budesonide develops recurrent episodes of severe, cramping abdominal pain with diarrhea occurring 30-60 minutes after meals. Symptoms improve with fasting. CT angiography shows no mesenteric ischemia. Gastric emptying study is normal. Upper endoscopy with duodenal biopsies shows villous blunting and intraepithelial lymphocytes. Serum tryptase during an episode is 45 ng/mL (normal <11.4). Which of the following is the most likely diagnosis?", "options": ["Mesenteric venous thrombosis with portal hypertensive enteropathy", "Systemic mastocytosis with gastrointestinal involvement", "Celiac disease with refractory sprue", "Abdominal angina from median arcuate ligament syndrome", "Bile acid malabsorption due to ileal dysfunction"], "answer": "B", "answer_index": 1, "explanation": "Systemic mastocytosis can present with postprandial abdominal pain, diarrhea, and flushing due to mast cell mediator release triggered by food. Elevated serum tryptase (>20 ng/mL) during symptoms is diagnostic. The duodenal findings represent mast cell infiltration rather than celiac disease. Mesenteric ischemia was ruled out by CT angiography. Median arcuate ligament syndrome causes epigastric pain but not diarrhea or elevated tryptase. Bile acid malabsorption does not explain the elevated tryptase or timing of symptoms.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: postprandial abdominal pain/diarrhea improving with fasting, elevated serum tryptase (45 ng/mL) during an episode, duodenal biopsy showing villous blunting and intraepithelial lymphocytes, and exclusion of mesenteric ischemia and gastroparesis. The elevated tryptase is a specific diagnostic marker for systemic mastocytosis, distinguishing it from other options. No logical issues; the vignette supports a single best answer. Medical accuracy is sound: the tryptase threshold (>20 ng/mL) and clinical presentation align with consensus diagnostic criteria for systemic mastocytosis with GI involvement. Minimal fix: None required; the item is unambiguous and accurate as written.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: postprandial abdominal pain/diarrhea improving with fasting, elevated serum tryptase (45 ng/mL) during an episode, duodenal biopsy showing villous blunting and intraepithelial lymphocytes, and exclusion of mesenteric ischemia and gastroparesis. The elevated tryptase is a specific diagnostic marker for systemic mastocytosis, distinguishing it from other options. No logical issues; the vignette supports a single best answer. Medical accuracy is sound: the tryptase threshold (>20 ng/mL) and clinical presentation align with consensus diagnostic criteria for systemic mastocytosis with GI involvement. Minimal fix: None required; the item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: Essential thrombocythemia (JAK2+), acute stroke in MCA territory, multiple small enhancing brain lesions, negative TTE for vegetations and negative blood cultures. The findings point to a hypercoagulable state with embolic strokes, and NBTE is a known complication of myeloproliferative neoplasms. The other options are less consistent: hydroxyurea leukoencephalopathy is symmetric and non-enhancing; AML transformation lacks blasts; JAK2 mutation is not linked to vasculitis; paradoxical embolism lacks a venous source and doesn't explain multiple enhancing lesions. No logical or medical inaccuracies. Minimal fix: None needed; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: Essential thrombocythemia (JAK2+), acute stroke in MCA territory, multiple small enhancing brain lesions, negative TTE for vegetations and negative blood cultures. The findings point to a hypercoagulable state with embolic strokes, and NBTE is a known complication of myeloproliferative neoplasms. The other options are less consistent: hydroxyurea leukoencephalopathy is symmetric and non-enhancing; AML transformation lacks blasts; JAK2 mutation is not linked to vasculitis; paradoxical embolism lacks a venous source and doesn't explain multiple enhancing lesions. No logical or medical inaccuracies. Minimal fix: None needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-006", "question": "A 31-year-old hematopoietic stem cell transplant recipient (day +45) for AML develops new-onset confusion and myoclonus. MRI brain shows symmetric T2 hyperintensities in the thalami and periaqueductal gray matter. CSF shows 5 WBCs/μL, protein 65 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). CSF PCR for HSV, VZV, EBV, CMV, and HHV-6 are negative. Metagenomic next-generation sequencing of CSF detects Astrovirus VA1/HMO-C RNA. Which of the following is the most appropriate management?", "options": ["Intravenous immunoglobulin 2 g/kg divided over 2-5 days", "Oral nitazoxanide 500 mg twice daily for 14 days", "Reduce immunosuppression and provide supportive care", "Intravenous ribavirin loading dose 33 mg/kg then 16 mg/kg every 6 hours", "Intrathecal administration of foscarnet 40 mg twice weekly"], "answer": "C", "answer_index": 2, "explanation": "Astrovirus VA1/HMO-C encephalitis in immunocompromised hosts has no proven antiviral therapy. Reduction of immunosuppression to allow immune reconstitution is the mainstay of management, along with supportive care. Intravenous immunoglobulin has been used but lacks proven efficacy. Nitazoxanide has in vitro activity but no clinical data in CNS infections. Ribavirin has poor CNS penetration and no proven benefit. Intrathecal foscarnet is used for HSV/VZV encephalitis but not for astrovirus.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: hematopoietic stem cell transplant recipient (immunocompromised), day +45, encephalitis features (confusion, myoclonus), MRI showing symmetric thalamic and periaqueductal gray hyperintensities, CSF with mild pleocytosis and normal glucose, negative PCR for common herpesviruses, and metagenomic NGS detecting Astrovirus VA1/HMO-C RNA. The findings point to a viral encephalitis with no proven specific antiviral therapy. Main logical issue: None; the stem provides sufficient detail to uniquely support reduction of immunosuppression and supportive care as the standard management for this rare infection. Main medical accuracy issue: None; the key and rationale align with current literature and guidelines for managing astrovirus encephalitis in immunocompromised hosts. Minimal fix: None required; the item is clear and accurate. However, to emphasize the lack of proven therapy, one could add 'No antiviral therapy has proven efficacy for Astrovirus VA1/HMO-C encephalitis' to the stem.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\":  \"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: hematopoietic stem cell transplant recipient (immunocompromised), day +45, encephalitis features (confusion, myoclonus), MRI showing symmetric thalamic and periaqueductal gray hyperintensities, CSF with mild pleocytosis and normal glucose, negative PCR for common herpesviruses, and metagenomic NGS detecting Astrovirus VA1/HMO-C RNA. The findings point to a viral encephalitis with no proven specific antiviral therapy. Main logical issue: None; the stem provides sufficient detail to uniquely support reduction of immunosuppression and supportive care as the standard management for this rare infection. Main medical accuracy issue: None; the key and rationale align with current literature and guidelines for managing astrovirus encephalitis in immunocompromised hosts. Minimal fix: None required; the item is clear and accurate. However, to emphasize the lack of proven therapy, one could add 'No antiviral therapy has proven efficacy for Astrovirus VA1/HMO-C encephalitis' to the stem.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]